Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Stefanie Hieke"'
Autor:
Herbert Schreiber, Iris-Katharina Penner, Tanja Maier, Stefanie Hieke-Schulz, Jost Leemhuis, Tjalf Ziemssen
Publikováno v:
Journal of Central Nervous System Disease, Vol 16 (2024)
Background Best supportive care (BSC) measures are an essential component for the management of primary progressive multiple sclerosis (PPMS). Objectives RETRO PPMS (ML39631) is the first study to systematically analyze the therapeutic journey and st
Externí odkaz:
https://doaj.org/article/a186cc90843e4577891e37c3c036ce53
Autor:
Martin S. Weber, Mathias Buttmann, Sven G. Meuth, Petra Dirks, Erwan Muros-Le Rouzic, Julius C. Eggebrecht, Stefanie Hieke-Schulz, Jost Leemhuis, Tjalf Ziemssen
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundReal-world relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) populations may be more diverse than in clinical trials. Here, we present a first analysis of safety, adherence and persistence data from a real-world cohort of
Externí odkaz:
https://doaj.org/article/5c361ada58c94ccf8af5b50ba90fce7e
Autor:
Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser, Tjalf Ziemssen
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overal
Externí odkaz:
https://doaj.org/article/d8e9e8de57af437a984b0d10fb418cba
Autor:
Mathias Mäurer, Klaus Tiel-Wilck, Eckard Oehm, Nils Richter, Michael Springer, Patrick Oschmann, Arndt Manzel, Stefanie Hieke-Schulz, Vera Zingler, Julia A. Kandenwein, Tjalf Ziemssen, Ralf A. Linker
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Background: With a large array of disease modifying therapies (DMTs) for relapsing-remitting MS (RRMS), identifying the optimal treatment option for the individual patient is challenging and switching of immunotherapies is often required. The objecti
Externí odkaz:
https://doaj.org/article/0fd09a02da39460790244fd7336013fa
Autor:
Monika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, Gabriele Ihorst, Heike Reinhardt, Alexander Zober, Stefanie Hieke, Corine Baayen, Stefan Jürgen Müller, Hermann Einsele, Pieter Sonneveld, Ola Landgren, Martin Schumacher, Ralph Wäsch
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
With growing numbers of elderly multiple myeloma patients, reliable tools to assess their vulnerability are required. The objective of the analysis herein was to develop and validate an easy to use myeloma risk score (revised Myeloma Comorbidity Inde
Externí odkaz:
https://doaj.org/article/4415a55bc1ec4533ac53a0b0413b2d98
Autor:
Monika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, Alexander Zober, Mandy Möller, Heike Reinhardt, Stefanie Hieke, Martin Schumacher, Ralph Wäsch
Publikováno v:
Haematologica, Vol 101, Iss 9 (2016)
This first validation of the International Myeloma Working Group geriatric assessment in 125 newly diagnosed multiple myeloma patients was performed using the International Myeloma Working Group score based on age, the Charlson Comorbidity Index and
Externí odkaz:
https://doaj.org/article/e4ebdd52f3ab469ebd631e6deaf11061
Autor:
Stefanie Hieke, Axel Benner, Richard F Schlenk, Martin Schumacher, Lars Bullinger, Harald Binder
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155226 (2016)
Clinical cohorts with time-to-event endpoints are increasingly characterized by measurements of a number of single nucleotide polymorphisms that is by a magnitude larger than the number of measurements typically considered at the gene level. At the s
Externí odkaz:
https://doaj.org/article/888780320d2a42caa8b2af5373c205c2
Autor:
David Wormser, Jost Leemhuis, Stefanie Hieke-Schulz, Vera Zingler, Tjalf Ziemssen, Petra Dirks, Heike Berthold
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Neurology
BMC Neurology
Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overall patient
Publikováno v:
Biometrical Journal. 62:822-835
Prognosis is usually expressed in terms of the probability that a patient will or will not have experienced an event of interest t years after diagnosis of a disease. This quantity, however, is of little informative value for a patient who is still e
Autor:
Wilko Weichert, Daniel-Christoph Wagner, Annette Lebeau, Johannes Ammann, Marion Kiechle, Hans Kreipe, Gustavo B. Baretton, Aurelia Noske, Wilfried Roth, Katja Steiger, Stefanie Hieke-Schulz, Peter Sinn, Carsten Denkert
Publikováno v:
Geburtshilfe und Frauenheilkunde.
Background Atezolizumab (an anti–PD-L1 antibody) has shown clinical activity alone or in combination with nab-paclitaxel in patients (pts) with first-line metastatic TNBC who have PD-L1 expression on their tumour-infiltrating immune cells (IC). We